Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer.

Saved in:
Bibliographic Details
Title: Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer.
Authors: Saillard M; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, Lausanne, Switzerland.; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.; Translational Research Centre in Onco-Hematology (CRTOH), University of Geneva, Geneva, Switzerland.; Geneva Centre for Inflammation Research (GCIR), University of Geneva, Geneva, Switzerland., Cenerenti M; Ludwig Institute for Cancer Research, Lausanne, Switzerland.; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.; Translational Research Centre in Onco-Hematology (CRTOH), University of Geneva, Geneva, Switzerland.; Geneva Centre for Inflammation Research (GCIR), University of Geneva, Geneva, Switzerland., Reichenbach P; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, Lausanne, Switzerland., Guillaume P; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, Lausanne, Switzerland., Su Z; Ludwig Institute for Cancer Research, Lausanne, Switzerland.; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.; Translational Research Centre in Onco-Hematology (CRTOH), University of Geneva, Geneva, Switzerland.; Geneva Centre for Inflammation Research (GCIR), University of Geneva, Geneva, Switzerland., Hafezi M; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, Lausanne, Switzerland., Schmidt J; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, Lausanne, Switzerland., Cesbron J; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, Lausanne, Switzerland., Genolet R; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, Lausanne, Switzerland., Queiroz L; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, Lausanne, Switzerland., Racle J; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, Lausanne, Switzerland.; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland., Villard J; Division of Nephrology, Geneva University Hospitals, Geneva, Switzerland.; Division of Transplantation Immunology, Geneva University Hospitals, Geneva, Switzerland., Renella R; Pediatric Hematology-Oncology Unit, Division of Pediatrics, Department 'Woman-Mother-Child,' University Hospital and Lausanne University, Lausanne, Switzerland., Michielin O; Molecular Modeling Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.; Department of Oncology, Geneva University Hospitals, Geneva, Switzerland., Zoete V; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, Lausanne, Switzerland.; Molecular Modeling Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland., Rivals JP; Plateforme clinique et translationnelle, Centre des thérapies expérimentales, University Hospital and Lausanne University, Lausanne, Switzerland., Irving M; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, Lausanne, Switzerland., Speiser DE; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland., Harari A; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, Lausanne, Switzerland., Gfeller D; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, Lausanne, Switzerland.; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland., Adotevi O; Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France., Ceppi F; Pediatric Hematology-Oncology Unit, Division of Pediatrics, Department 'Woman-Mother-Child,' University Hospital and Lausanne University, Lausanne, Switzerland., Coukos G; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, Lausanne, Switzerland., Romero P; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, Lausanne, Switzerland., Jandus C; Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, Lausanne, Switzerland.; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.; Translational Research Centre in Onco-Hematology (CRTOH), University of Geneva, Geneva, Switzerland.; Geneva Centre for Inflammation Research (GCIR), University of Geneva, Geneva, Switzerland.
Source: Science advances [Sci Adv] 2025 Jun 27; Vol. 11 (26), pp. eadu5754. Date of Electronic Publication: 2025 Jun 27.
Publication Type: Journal Article
Journal Info: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101653440 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2375-2548 (Electronic) Linking ISSN: 23752548 NLM ISO Abbreviation: Sci Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2375-2548
DOI:10.1126/sciadv.adu5754